Blog
RSS FeedPosted by Michael Wonder on 11 Aug 2019
Patient groups push back against Gilead's pricey HIV prevention treatment
7 August 2019 - Gilead Sciences hopes to soon introduce a pricey new pill to prevent HIV in people at risk ...
Posted by Michael Wonder on 11 Jul 2019
How Australia could almost eradicate H.I.V. transmissions
10 July 2019 - It took universal health care, political will and a health campaign designed to terrify the public, ...
Posted by Michael Wonder on 09 Jul 2019
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
9 July 2019 - The long-acting injectable regimen has been granted priority review status by the FDA, with a target approval ...
Posted by Michael Wonder on 03 Jul 2019
ViiV Healthcare receives EU marketing authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection
3 July 2019 - Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug ...
Posted by Michael Wonder on 02 Jul 2019
HIV diagnoses in Australia hit 18-year low, but there is still a way go
3 July 2019 - Australia has solidified its reputation as a world leader in HIV prevention, recording its lowest number ...
Posted by Michael Wonder on 02 Jul 2019
FDA continues to encourage ongoing education about the benefits and risks associated with PrEP, including additional steps to help reduce the risk of getting HIV
1 July 2019 - The U.S. FDA approved Truvada (emtricitabine/tenofovir disoproxil fumarate) in 2004 for the treatment of HIV-1 infection in ...
Posted by Michael Wonder on 14 May 2019
A million Americans need this drug. Trump’s deal won’t help enough of them.
13 May 2019 - A donation of HIV prevention drugs from the pharmaceutical giant Gilead could benefit shareholders more than patients. ...
Posted by Michael Wonder on 30 Apr 2019
Janssen announces submission of new drug application to U.S. FDA for the first monthly, injectable, two drug regimen of rilpivirine and cabotegravir for treatment of HIV
29 April 2019 - If approved, the rilpivirine and cabotegravir regimen would be the first-ever long-acting injectable treatment for adults living ...
Posted by Michael Wonder on 25 Mar 2019
HIRA puts brakes on Gilead’s AIDS treatment receiving reimbursement
22 March 2019 - The reimbursement plan for Gilead Science Korea’s Biktarvy, an acquired immune deficiency syndrome (AIDS) treatment, has been ...
Posted by Michael Wonder on 25 Mar 2019
19,000 Australians now using PBS subsidised anti-HIV drugs
25 March 2019 - About 19,000 Australians have taken advantage of anti-HIV drugs in the first two years of groundbreaking ...
Posted by Michael Wonder on 24 Jan 2019
U.S. FDA accepts sNDAs for Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
23 January 2019 - Potential new indication would expand use to allow treatment-experienced adults living with HIV-1 whose virus is suppressed ...
Posted by Michael Wonder on 20 Dec 2018
Decisions relating to the funded brands of some anti-retroviral treatments for HIV
20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in ...
Posted by Michael Wonder on 30 Nov 2018
FDA announces pilot program with WHO to expedite review of HIV drug applications
30 November 2018 - The U.S. FDA today announced a plan to work with the WHO to pilot a process to ...
Posted by Michael Wonder on 16 Oct 2018
Proposal to award sole supply and change some anti-retroviral brands
16 October 2018 - PHARMAC is seeking feedback on a proposal to make several changes to funding of anti-retroviral therapies ...
Posted by Michael Wonder on 13 Jul 2018
Gilead receives approval in Canada for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for the treatment of HIV-1 infection
12 July 2018 - Gilead Sciences Canada today announced that Health Canada has granted a notice of compliance for Biktarvy (bictegravir ...